The UCPI Biostatistics Facility (BF) provides statistical expertise in study design and data analysis for members of UPCI. This shared resource is cancer-center managed. Statisticians within the Facility collaborate on developing protocols for investigator-initiated clinical trials (IITs), and research plans and proposals for laboratory-based studies, population-science studies, and clinical investigations. Members of the Facility perform statistical analyses of data from these studies, substantively interpret results in collaboration with their UPCI colleagues, and author or co-author publications. Biostatistics personnel are involved extensively in cancer center-wide activities. These include participation at regular program meetings;service on UPCI committees for research oversight, protocol review, and data and safety monitoring;and collaborations with Clinical Research Services (CRS) and Cancer Informatics Services (CIS) to enhance UPCI operations and systems supporting IITs. Members of the Facility are active on review committees for the National Cancer Institute and as members of data and safety monitoring boards for the University of Pittsburgh Medical Center (UPMC). The Facility is also committed to developing statistical software for the design and analysis of laboratory-based studies and clinical trials that can be applied across multiple research programs and systems, such as that for patient registration and randomization, which can support UPCI IITs. The two guiding principles for the Facility are excellence in what we do and efficiency in accomplishing our work.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705419
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$307,479
Indirect Cost
$104,072
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Lontos, Konstantinos; Tsagianni, Anastasia; Yuan, Jian-Min et al. (2018) Location matters in early stage nodal diffuse large B-cell lymphoma. Leuk Lymphoma :1-4

Showing the most recent 10 out of 1187 publications